EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 416-430

  Soria, Jean Charles ^a   Mok, Tony S ^b   Cappuzzo, Federico ^c   Jänne, Pasi A ^d  

^a Universite Paris Sud   (France)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Livorno Hospital   (Italy)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Biological markers; Carcinoma; Epidermal growth factor; Erlotinib; Gefitinib; Mutation; Non small cell lung; Oncogenes; Receptor

Indexed keywords

B RAF KINASE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; EXON; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; EXONS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861203302     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.10.003     Document Type: Review

References (176)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
2. D'Addario G., Fruh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
3. Hotta K., Fujiwara Y., Matsuo K., Suzuki T., Kiura K., Tabata M., et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007, 109(5):939-948.
4. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353(2):172-187.
5. Tarceva® Summary of Product Characteristics. Welwyn Garden City, UK: Roche Registration Ltd.; 2011.
6. Iressa® Summary of Product Characteristics. AstraZeneca, Macclesfield, UK; 2011.
7. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22(5):777-784.
8. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22(5):785-794.
9. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
10. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25(12):1545-1552.
11. Gridelli C., Ciardiello F., Feld R., Butts C.A., Gebbia V., Genestreti G., et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial. J Clin Oncol 2010, 28(15 Suppl. 1).
12. Lee S., Rudd R., Khan I., Upadhyay S., Lewanski C.R., Falk S., et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010, 28(15 Suppl. 1).
13. Shepherd F.A., Rodrigues P.J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
14. Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., Von P.J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496):1527-1537.
15. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 22;372(9652):1809-1818.
16. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26(26):4244-4252.
17. Lee D.H., Park K., Kim J.H., Lee J.S., Shin S.W., Kang J.H., et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16(4):1307-1314.
18. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
19. Takeda K., Hida T., Sato T., Ando M., Seto T., Satouchi M., et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010, 28(5):753-760.
20. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009, 122(1):1-8.
21. Laurent-Puig P., Lievre A., Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009, 15(4):1133-1139.
22. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28(5):744-752.
23. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353(2):133-144.
24. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97(9):643-655.
25. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7(3):603-607.
26. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S9-15.
27. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002, 20(4):975-981.
28. Jeon Y.K., Sung S.W., Chung J.H., Park W.S., Seo J.W., Kim C.W., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54(3):387-398.
29. Clark G.M., Zborowski D.M., Culbertson J.L., Whitehead M., Savoie M., Seymour L., et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006, 1(8):837-846.
30. Clark G.M., Zborowski D.M., Santabarbara P., Ding K., Whitehead M., Seymour L., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21. Clin Lung Cancer 2006, 7(6):389-394.
31. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21(20):3798-3807.
32. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization aAssay. Diagn Pathol 2006, 1:19.
33. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(31):5034-5042.
34. Hirsch F.R., Varella-Garcia M., Dziadziuszko R., Xiao Y., Gajapathy S., Skokan M., et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008, 14(19):6317-6323.
35. Schneider C.P., Heigener D., Schott-von-Romer K., Gutz S., Laack E., Digel W., et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol 2008, 3(12):1446-1453.
36. Zhu C.Q., da Cunha S.G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26(26):4268-4275.
37. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
38. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
39. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
40. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
41. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
42. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
43. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
44. Kancha R.K., on Bubnoff N., Peschel C., Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009, 15(2):460-467.
45. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
46. Cortes-Funes H., Gomez C., Rosell R., Valero P., Garcia-Giron C., Velasco A., et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005, 16(7):1081-1086.
47. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520.
48. Han S.W., Kim T.Y., Jeon Y.K., Hwang P.G., Im S.A., Lee K.H., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12(8):2538-2544.
49. Eck M.J., Yun C.H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 2010, 1804(3):559-566.
50. Yang C., Shih J., Chao T., Tsai T., Yu C., Yang P., et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial. J Clin Oncol 2008, 26(Suppl). abstr 8026.
51. Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(18):3076-3083.
52. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10(5):425-435.
53. John T., Liu G., Tsao M.S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl 1):S14-S23.
54. Ellison G., Donald E., McWalter G., Knight L., Fletcher L., Sherwood J., et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 29:132.
55. Gridelli C., De Marinis F., Di Maio M., Cortinovis D., Cappuzzo F., Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer 2011, 72(1):3-8.
56. Pan Q., Pao W., Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005, 7(3):396-403.
57. Ohnishi H., Ohtsuka K., Ooide A., Matsushima S., Goya T., Watanabe T. A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. Diagn Mol Pathol 2006, 15(2):101-108.
58. He C., Liu M., Zhou C., Zhang J., Ouyang M., Zhong N., et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009, 125(10):2393-2399.
59. Mack P.C., Holland W.S., Burich R.A., Sangha R., Solis L.J., Li Y., et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009, 4(12):1466-1472.
60. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028.
61. Kawahara A., Yamamoto C., Nakashima K., Azuma K., Hattori S., Kashihara M., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16(12):3163-3170.
62. Su Z., as-Santagata D., Duke M., Hutchinson K., Lin Y.L., Borger D.R., et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011, 13(1):74-84.
63. Okudela K., Woo T., Kitamura H. KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int 2010, 60(10):651-660.
64. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69(3):272-278.
65. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23(25):5900-5909.
66. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10):2890-2896.
67. Marchetti A., Milella M., Felicioni L., Cappuzzo F., Irtelli L., Del Grammastro M., et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11(10):1084-1092.
68. Loriot Y., Mordant P., Deutsch E., Olaussen K.A., Soria J.C. Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nat Rev Clin Oncol 2009, 6(9):528-534.
69. Roberts P.J., Stinchcombe T.E., Der C.J., Socinski M.A. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010, 28(31):4769-4777.
70. De Roock W., Jonker D.J., Di Nicolantonic F., Sartore-Bianchi A., Tu D., Siena S., et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304(16):1812-1820.
71. Pellegrini C., Falleni M., Marchetti A., Cassani B., Miozzo M., Buttitta F., et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003, 9(10 Pt 1):3645-3652.
72. Nakamura H., Kawasaki N., Taguchi M., Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2005, 103(9):1865-1873.
73. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005, 23(22):5007-5018.
74. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005, 65(5):1642-1646.
75. Buttitta F., Barassi F., Fresu G., Felicioni L., Chella A., Paolizzi D., et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006, 119(11):2586-2591.
76. Doebele R.C., Oton A.B., Peled N., Camidge D.R., Bunn P.A. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 2010, 69(1):1-12.
77. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10(1):25-38.
78. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009, 106(2):474-479.
79. Kelly R.J., Carter C., Giaccone G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 2010, 28(28):e507-e510.
80. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
81. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
82. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115(8):1723-1733.
83. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46(10):1773-1780.
84. Xalkori® [package insert]. New York, NY: Pfizer; 2011.
85. Paik J.H., Choe G., Kim H., Choe J.Y., Lee H.J., Lee C.T., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6(3):466-472.
86. Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., Aubry M.C., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6(3):459-465.
87. Wojtalla A., Arcaro A. Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol 2011, 80(2):278-290.
88. Yamamoto H., Shigematsu H., Nomura M., Lockwood W.W., Sato M., Okumura N., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68(17):6913-6921.
89. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009, 15(14):4554-4560.
90. Marchetti A., Felicioni L., Malatesta S., Grazia S.M., Guetti L., Chella A., et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011, 29(26):3574-3579.
91. Korc M., Friesel R.E. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9(5):639-651.
92. Albert S., Serova M., Dreyer C., Sablin M.P., Faivre S., Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010, 19(8):919-930.
93. Janku F., Stewart D.J., Kurzrock R. Targeted therapy in non-small-cell lung cancer - is it becoming a reality?. Nat Rev Clin Oncol 2010, 7(7):401-414.
94. Pal S.K., Figlin R.A., Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 2010, 9(7):1931-1944.
95. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., Kris M.G., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29(15):2046-2051.
96. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2(62):62ra93.
97. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Xhou W., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1:OF76-OF87.
98. Cappuzzo F., Tallini G., Finocchiaro G., Wilson R.S., Ligorio C., Giordano L., et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010, 21(3):562-567.
99. Dziadziuszko R., Merrick D.T., Witta S.E., Mendoza A.D., Szostakiewicz B., Szymanowska A., et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010, 28(13):2174-2180.
100. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11(16):5878-5885.
101. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(3 Pt 1):839-844.
102. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Janne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
103. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at 13th World Conference on Lung Cancer, San Francisco. J Thorac Oncol 2009 [abstr PRS 4].
104. Jänne P.A., Wang X.F., Socinski M.A., Crawford J., Capelletti M., Edelman M.J., et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010, 28(15 Suppl.). [abstr 7503].
105. Hirsch F.R., Kabbinavar F., Eisen T., Martins R., Schnell F.M., Dziadziuszko R., et al. A randomized, Phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29(26):3567-3573.
106. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X., Wang C., et al. Efficacy results from the randomised phase iii optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in chinese advanced nonsmall-cell lung cancer (NSCLC) patients (PTS) with egfr activating mutations. Ann Oncol 2010, 21(Suppl. 8):viii6.
107. Rosell R., Gervais R., Vergnenegre A., Massuti B., Felip E., Cardenal F., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011, 29(Suppl.). [abstr 7503].
108. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(13):3908-3914.
109. Sholl L.M., Yeap B.Y., Iafrate A.J., Holmes-Tisch A.J., Chou Y.P., Wu M.T., et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009, 69(21):8341-8348.
110. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006, 66(16):8163-8171.
111. Shepherd F.A., Tsao M.S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006, 24(7):1219-1220.
112. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346.
113. Kim Y.T., Kim T.Y., Lee D.S., Park S.J., Park J.Y., Seo S.J., et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008, 59(1):111-118.
114. Kosaka T., Yatabe Y., Onozato R., Kuwano H., Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009, 4(1):22-29.
115. Lin C.C., Hsu H.H., Sun C.T., Shih J.Y., Lin Z.Z., Yu C.J., et al. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. J Thorac Oncol 2010, 5(9):1424-1429.
116. Tsao M.S., Sakurada A., Ding K., viel-Ronen S., Ludkovski O., Liu N., et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2011, 6(1):139-147.
117. Soria J.C., Massard C., Le C.T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Ann Oncol 2010, 21(12):2324-2332.
118. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
119. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105(6):2070-2075.
120. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12(21):6494-6501.
121. Bean J., Riely G.J., Balak M., Marks J.L., Ladanyi M., Miller V.A., et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14(22):7519-7525.
122. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26(15):2442-2449.
123. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006, 66(16):7854-7858.
124. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377.
125. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17(5):1160-1168.
126. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17(6):1616-1622.
127. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104(52):20932-20937.
128. Beau-Faller M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol 2008, 3(4):331-339.
129. Cappuzzo F., Janne P.A., Skokan M., Finocchiaro G., Rossi E., Ligorio C., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009, 20(2):298-304.
130. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
131. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16(22):5489-5498.
132. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14(10):2895-2899.
133. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68(22):9479-9487.
134. Matsumoto K., Nakamura T. Hepatocyte growth factor and the met system as a mediator of tumor-stromal interactions. Int J Cancer 2006, 119(3):477-483.
135. Spigel D., Ervin T., Ramlau R., Daniel D., Goldschmidt J., Krzakowski M., et al. Randomized multicenter double-blind placebocontrolled phase ii study evaluating metmab, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-smallcell lung cancer. Ann Oncol 2010, 21(Suppl. 8):viii7. [LBA15].
136. Sequist L.V., Waltman B.A., as-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
137. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471(7339):523-526.
138. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28(2):357-360.
139. Jänne P.A. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 2008, 60(Suppl. 2):S3-S9.
140. Kuang Y., Rogers A., Yeap B.Y., Wang L., Makrigiorgos M., Vetrand K., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15(8):2630-2636.
141. Oh Y.H., Kim Y., Kim Y.P., Seo S.W., Mitsudomi T., Ahn M.J., et al. Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn 2010, 12(5):644-652.
142. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25(18):2528-2533.
143. Costa D.B., Nguyen K.S., Cho B.C., Sequist L.V., Jackman D.M., Riely G.J., et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14(21):7060-7067.
144. Lee D.H., Kim S.W., Suh C., Yoon D.H., Yi E.J., Lee J.S. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008, 19(12):2039-2042.
145. Vasile E., Tibaldi C., Chella A., Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol 2008, 3(8):912-914.
146. Vasile E., Tibaldi C., Falcone A. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?. Ann Oncol 2009, 20(4):790-791.
147. Riely G.J., Kris M.G., Zhao B., Akhurst T., Milton D.T., Moore E., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13(17):5150-5155.
148. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
149. Yang C., Shih J., Su W., Hsia T., Sequist L.V., Chang G., et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (lux-lung 2). Ann Oncol 2010, 21(Suppl. 8):viii123.
150. Miller V.A., Hirsh V., Cadranel J., Chen Y.-M., Park K., Kim S.-W., et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) 1 best supportive care (BSC) versus placebo 1 BSC in patients with nsclc failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-lung 1). Ann Oncol 2010, 21(Suppl 8):viii1.
151. Miller VA, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, et al. Subgroup analysis of LUX-Lung 1: a randomized Phase III trial of afatinib (BIBW 2992)+best supportive care (BSC) versus placebo+BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib. Oral presentation at Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, USA. Available from: http://www.oncologymeetings.org/Meetings/UpcomingMeetings/Thoracic/ScientificProgram/pres/documents/ThorPlenaryMiller.pdf.
152. Regales L., Gong Y., Shen R., De Stanchina E., Vivanco I., Goel A., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119(10):3000-3010.
153. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29(Suppl.). [abstr 7525].
154. Mok T., Spigel D.R., Park K., Socinski M.A., Tung S.Y., Kim D., et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15 Suppl.). [Abstr 7537].
155. Park K., Heo D.S., Cho B., Kim D., Ahn M., Lee S., et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. J Clin Oncol 2010, 28(15 Suppl.). [abstr 7599].
156. de La Motte R.T., Galluzzi L., Olaussen K.A., Zermati Y., Tasdemir E., Robert T., et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007, 67(13):6253-6262.
157. Bahleda R., Felip E., Herbst R.S., Hanna N.H., Laurie S.A., Shepherd F.A., et al. Phase I multicenter trial of BMS-690514: safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 2008, 26(15 Suppl.). Abstr 2564.
158. Sbar E., Besse B., Felip E., Shaw A., Ahn M.-J., Salvati M., et al. A double-blind, randomized, parallel, two-arm phase II trial of BMS-690514 versus erlotinib in previous chemotherapy-treated non-small cell lung cancer (NSCLC) patients: a safety review. J Thorac Oncol 2010, 5(12 Suppl. 5):S385.
159. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462(7276):1070-1074.
160. de Boer R.H., Arrieta O., Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(8):1067-1074.
161. Natale R.B., Bodkin D., Govindan R., Sleckman B.G., Rizvi N.A., Capo A., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009, 27(15):2523-2529.
162. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626.
163. Lee J., Hirsh V., Park K., Qin S., Blajman C.R., Perng R., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28(15 Suppl.). [abstr 7525].
164. Miller V.A., Wakelee H.A., Lara P.N., et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol 2008, 26(Suppl.). [abstr 8028].
165. Rizvi N.A., Kris M.G., Miller V.A., et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from Phase 2. J Clin Oncol 2008, 26(Suppl.). [abstr 8053].
166. Pirker R., Pereira J.R., Szczesna A., Von P.J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
167. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28(6):911-917.
168. Khambata-Ford S., Harbison C.T., Hart L.L., Awad M., Xu L.A., Horak C.E., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(6):918-927.
169. Neal J.W., Heist R.S., Fidias P., Temel J.S., Huberman M., Marcoux J.P., et al. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol 2010, 5(11):1855-1858.
170. Riely G.J., Janjigian Y.Y., Azzoli C.G., Pietanza M., Krug L.M., Rizvi N.A., et al. Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. J Clin Oncol 2010, 28(15 Suppl.). [abstr 7557].
171. Price K.A., Azzoli C.G., Krug L.M., Pietanza M.C., Rizvi N.A., Pao W., et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 2010, 5(10):1623-1629.
172. Yap T.A., Olmos D., Brunetto A.T., Tunariu N., Barriuso J., Riisnaes R., et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011, 29(10):1271-1279.
173. Karp D.D., Paz-Ares L.G., Novello S., Haluska P., Garland L., Cardenal F., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27(15):2516-2522.
174. Cardoso F., Senkus-Konefka E., Fallowfield L., Costa A., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v15-v19.
175. Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., Zhou Q., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16(22):5581-5590.
176. Underhill C., Toulmonde M., Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011, 22(2):268-279.